Login to Your Account

FDA Panel to Debate Efficacy, Safety of Pfizer's JAK Inhibitor

By Mari Serebrov
Washington Editor

Tuesday, May 8, 2012
Whether Pfizer Inc. cleared the efficacy bar with tofacitinib, its first-in-class JAK inhibitor for rheumatoid arthritis (RA), will be open for debate at Wednesday's meeting of the FDA's Arthritis Advisory Committee (AAC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription